Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2013007921
pages 409-434

Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors

Alexander Richardson
Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, 2006, Australia
Zaklina Kovacevic
Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, 2006, Australia
Des R. Richardson
Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, 2006, Australia

SINOPSIS

Pancreatic cancer is the fourth leading cause of cancer-related deaths worldwide in both men and women. It presents late with non-specific symptoms, which makes it difficult to diagnose until the cancer has progressed and metastasized. Metastasis is facilitated by the epithelial-to-mes-enchymal transition (EMT), which is promoted via the oncogenic transforming growth factor beta (TGFβ), Wnt, and nuclear factor kappa B (NFκB) signaling pathways. However, recent studies have demonstrated that the EMT can be inhibited by novel anti-cancer agents known as thiosemicarbazone iron chelators. These novel agents also up-regulate the metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), which can restore normal signaling to the cell and suppresses metastasis via inhibition of the EMT. Through the ability of iron chelators to up-regulate NDRG1 expression and affect multiple molecular targets, these agents have the potential to maintain the epithelial phenotype of cancer cells and may lead to improved survival rates for patients with late-stage disease.


Articles with similar content:

Regulating RNA Binding Motif 5 Gene Expression− A Novel Therapeutic Target for Lung Cancer
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu
A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Yuhao Wang, Benjamin Bonavida
The Novel Role of Yin Yang 1 in the Regulation of Epithelial to Mesenchymal Transition in Cancer Via the Dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Stavroula Baritaki, Benjamin Bonavida
S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor−Negative Breast Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.3, 2012, issue 2
Robert Cheng, Julie Heinecke, David A. Wink, Lisa A. Ridnour, Christopher H. Switzer, Sharon Glynn, Amy Burke, Stefan Ambs
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada